Impact of synbiotic therapy on periodontal status and molecular biomarkers in patients with chronic periodontitis concurrent with obesity and dysbiosis: a randomized clinical trial

2026

Полный текст Открытый доступ: Gold Метаданные (CSL-JSON)
DOI 10.17816/dent706126
Достоверность данных 70 средняя
Как считается эта оценка

Складывается из проверяемых признаков самой записи: есть ли у статьи DOI, сколько независимых источников подтвердили её данные, заполнены ли обязательные поля и насколько свежо последнее подтверждение. Снижают оценку расхождения между источниками и отсутствие идентификатора. Значение от 80 означает, что запись опубликована без дополнительной проверки; от 60 до 79 — что она опубликована с пониженной достоверностью и ручная проверка желательна. Запись, выверенную редактором вручную, пересчёт не опускает ниже 90. Это оценка наших данных о статье, а не оценка самой статьи.

Аннотация

BACKGROUND: According to published data, the pathogenetic link between chronic periodontitis and morbid obesity (body mass index 40 kg/m²) is mediated by gastrointestinal dysbiosis, systemic inflammation, oxidative stress, and endotoxemia. Bacterial toxins and inflammatory mediators circulating in the bloodstream of obese patients contribute to progressive destruction of periodontal tissues and reduce the effectiveness of regenerative processes during periodontitis treatment. Therapy for such patients should include measures to normalize the intestinal microbiota composition. AIM: To evaluate the effect of conservative treatment with probiotics on periodontal tissue status and molecular biomarkers in patients with periodontitis concurrent with obesity and dysbiosis. METHODS: The study included 70 individuals (aged 45–59 years) with chronic periodontitis, morbid obesity, and intestinal dysbiosis, divided into two equal groups. Patients in group 1 (n = 35) received, in addition to standard therapy, a complex of live Lactobacillus and/or Bifidobacterium strains (Bifilyuks, Russia) combined with a prebiotic (lactitol) and metabiotics. Patients in group 2 (n = 35) received standard periodontitis therapy consisting of ultrasonic removal of dental deposits, surface polishing, and antiseptic treatment. Treatment efficacy was assessed at 3, 6, 9, and 12 months using the Russell Periodontal Index and probing pocket depth. Additionally, cytokine and osteomarker concentrations in periodontal exudate were monitored at 3 and 6 months. RESULTS: After treatment, both groups showed significant reductions in periodontal index scores and probing pocket depth, indicating resolution of periodontal inflammation. However, the additional use of probiotics in group 1 resulted in a more pronounced reduction in the Russell Periodontal Index compared to group 2, particularly during the first 3–9 months. Concentrations of interleukin-8, tumor necrosis factor-alpha, and cathepsin K were also significantly lower after treatment in group 1. CONCLUSION: The use of synbiotics as part of comprehensive conservative treatment in patients with periodontitis, obesity, and dysbiosis demonstrated high anti-inflammatory efficacy, as evidenced by clinical parameters and molecular markers of inflammation and bone resorption.